Biomea Fusion, Inc.

NasdaqGS BMEA

Biomea Fusion, Inc. Shareholders' Equity for the quarter ending September 30, 2024

Biomea Fusion, Inc. Shareholders' Equity is NA for the quarter ending September 30, 2024. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Biomea Fusion, Inc. Shareholders' Equity for the quarter ending September 30, 2023 was USD 199.61 M, a 52.80% change year over year.
Biomea Fusion, Inc. Shareholders' Equity for the quarter ending September 30, 2022 was USD 130.63 M, a -31.72% change year over year.
Biomea Fusion, Inc. Shareholders' Equity for the quarter ending September 30, 2021 was USD 191.33 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGS: BMEA

Biomea Fusion, Inc.

CEO	Mr. Thomas Andrew Butler
IPO Date	April 16, 2021
Location	United States
Headquarters	900 Middlefield Road
Employees	107
Sector	Healthcare
Industries Biotechnology Chemicals & Advanced Materials Clinical Trials Pharmaceuticals

Description

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Key trends

Past 5 years